All In Biotech

Drug Trial Radar · NCT07234942

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 Following Intrathecal Administration in Participants With Early Symptomatic Alzheimer's Disease

Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

6

Actual

Start

Jan 27, 2026

Primary completion

Mar 31, 2027

Study completion Mar 31, 2027

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Nov 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics following administration of RO7812653 in participants with eAD.

Conditions

  • Alzheimer's Disease

Interventions

  • RO7812653Drug

    Participants will receive RO7812653 as per the schedule in the protocol

  • PlaceboDrug

    Participants will receive placebo as per the schedule in the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Adverse EventsTime frame: Up to approximately 40 weeks
  2. Change From Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) ScoresTime frame: Up to approximately 40 weeks

Locations

12 sites in 5 countries. Site status is shown where the registry gives one.

  • Toronto Western Hospital

    Toronto, Ontario, Canada

  • Montreal Neurological Institute Clinical Research Unit

    Montreal, Quebec, Canada

  • Brain Research Center Amsterdam

    Amsterdam, North Holland, Netherlands

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain

  • Hospital Universitario Reina Sofia

    Córdoba, Spain

  • Hospital General de Catalunya

    Sant Cugat del Vallès, Barcelona, Spain

  • Sahlgrenska Universitetssjukhuset, Mlndal Sjukhus

    Mlndal, Sweden

  • Karolinska Universitetssjukhuset

    Solna, Sweden

  • National Hospital For Neurology and Neurosurgery

    London, United Kingdom

  • Institute of Psychiatry, Psychology and Neuroscience;Department of Old Age Psychiatry

    London, Greater London, United Kingdom

  • Southampton General Hospital

    Southampton, Hampshire, United Kingdom

  • Queen Elizabeth Hospital

    Glasgow, Strathclyde, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.